Redefining what’s possible in cystic fibrosis treatment
Our vision is to fully normalize CFTR function
We’re developing novel small molecule therapies targeting the most common genetic mutation affecting cystic fibrosis (CF) patients, ΔF508, with the goal of normalizing CFTR function.
DC / IND-Enabling
Every day I get to go to work and interact with an awesome group of people. Even cooler than that, we all do work that will positively impact patients’ lives!
Direct…but from every conceivable angle! That’s how I would describe the drug discovery strategy at Sionna. I am grateful for the opportunity to work toward the goal of normal CFTR function for CF patients.